Form 8-K · Current report
Solventum 8-K, filed Aug 5, 2026
- Filed
- CIK
- 0001964738
- Accession no.
- 0001964738-26-000045
Summary
Solventum reported second-quarter 2026 sales of $2.2 billion, up 2.2% on a reported basis and 9.5% organically, and said it intends to separate its Health Information Systems business segment while raising full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow.
Key points
- Second-quarter GAAP diluted earnings per share were $0.53; adjusted diluted earnings per share were $2.55, a 50.9% increase.
- Operating cash flow was $227 million and free cash flow was $144 million.
- Solventum increased its full-year 2026 adjusted EPS guidance to $7.10 to $7.20, from the upper end of its prior $6.40 to $6.60 range.
- CEO Bryan Hanson said the quarter's results were ahead of expectations and that the company remains on track to achieve its long-term objectives.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition On August 5, 2026, Solventum issued a press release reporting second-quarter 2026 financial results (attached hereunder as Exhibit 99.1 and incorporated herein by reference). Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99.1 Press Release, dated as of August 5, 2026, of Solventum Corporation (furnished pursuant to Item 2.02 hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). Exhibit 99.1: EX-99.1 2 q22026-8kerexx991.htm EX-99.1 Exhibit 99.1 Solventum Reports Second Quarter 2026 Financial Results •Reported sales increased 2.2%; …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.